MedPath

GILEAD SCIENCES SL

🇺🇸United States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain
Clinical Trials
Related News

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Phase 2
Active, not recruiting
Conditions
Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections
Interventions
Drug: ATV
Drug: Third Unboosted Drug
Drug: DRV
Drug: LPV/r
Drug: BR
Drug: F/TAF TOS
First Posted Date
2013-12-20
Last Posted Date
2025-01-22
Lead Sponsor
Gilead Sciences
Target Recruit Count
133
Registration Number
NCT02016924
Locations
🇺🇸

Pediatric Infectious Disease Associates, Long Beach, California, United States

🇺🇸

Peter Morton Medical Building, Los Angeles, California, United States

🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

and more 20 locations

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Phase 2
Completed
Conditions
Chronic HCV Infection
Interventions
Drug: LDV/SOF
First Posted Date
2013-12-12
Last Posted Date
2018-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
334
Registration Number
NCT02010255
Locations
🇫🇷

Hospital Mondor \\ Service d'Hépatologie et de Gastroentérologie,, Créteil, France

🇦🇹

Medizinische Universitat Wien, Wien, Austria

🇩🇪

Universitätsklinikum RWTH Aachen, Aachen, Germany

and more 31 locations

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Phase 1
Completed
Conditions
Hepatitis C Virus
Interventions
First Posted Date
2013-12-06
Last Posted Date
2020-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
19
Registration Number
NCT02002767

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Phase 2
Completed
Conditions
HCV Infection
Interventions
Drug: LDV/SOF
First Posted Date
2013-11-19
Last Posted Date
2018-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
100
Registration Number
NCT01987453

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Phase 2
Completed
Conditions
Chronic HCV Infection
Interventions
Drug: LDV/SOF
First Posted Date
2013-11-14
Last Posted Date
2018-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
101
Registration Number
NCT01984294

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Phase 3
Terminated
Conditions
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2013-11-11
Last Posted Date
2018-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
57
Registration Number
NCT01980875
Locations
🇺🇸

Sansum Clinic, Santa Barbara, California, United States

🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

🇫🇷

Centre Hospitalier de Perpignan, Perpignan Cedex 9, France

and more 15 locations

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3
Terminated
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Placebo
First Posted Date
2013-11-11
Last Posted Date
2018-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
311
Registration Number
NCT01980888
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇨🇦

Cancercare Manitoba - Maccharles Unit, Winnipeg, Manitoba, Canada

🇺🇸

Franciscan Physician Network Oncology & Hematology, Indianapolis, Indiana, United States

and more 87 locations

Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Phase 3
Completed
Conditions
Chronic HCV Infection
Interventions
Drug: LDV/SOF
First Posted Date
2013-11-05
Last Posted Date
2018-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
341
Registration Number
NCT01975675

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Phase 3
Completed
Conditions
HIV-1
HIV Infections
Acquired Immunodeficiency Syndrome
Interventions
Drug: Baseline DRV- containing ARV regimen
Drug: DRV
First Posted Date
2013-10-24
Last Posted Date
2018-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
158
Registration Number
NCT01968551
Locations
🇺🇸

Dupont Circle Physician's Group, Washington, District of Columbia, United States

🇺🇸

The Miriam Hospital, Providence, Rhode Island, United States

🇺🇸

Gary J.Richmond, MD, P.A., Fort Lauderdale, Florida, United States

and more 59 locations

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Phase 3
Completed
Conditions
HIV
HIV Infections
Acquired Immunodeficiency Syndrome
Interventions
Drug: Placebo
Drug: Current failing ARV regimen
Drug: ATV
First Posted Date
2013-10-23
Last Posted Date
2018-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
55
Registration Number
NCT01967940
Locations
🇷🇺

Regional state budget health agency Krasnoyarsk Regional Center for Prevention and Control of AIDS, Krasnoyarsk, Russian Federation

🇺🇸

Midway Immunology and Research center, Fort Pierce, Florida, United States

🇺🇬

Joint Clinical Research Centre, Kampala, Uganda

and more 12 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy